C000104936 Fees and Costs — Health Sciences Fund, Class NAV
Data updated: 2025-04-28
The net expense ratio is 0.85%: a 0.77% management fee plus 0.09% other expenses, less a 0.01% fee waiver. There are no sales loads or redemption fees. In fiscal 2024 the fund paid $70K in broker commissions, 0.0271% of average net assets, and portfolio turnover was 49%.
C000104936 Fees and Expenses
Annual operating expenses and sales charges of C000104936. Prospectus, as of December 31, 2024.
| Annual operating expenses | |
|---|---|
| Management fee | 0.77% |
| 12b-1 fee | — |
| Other expenses | 0.09% |
| Gross expense ratio | 0.86% |
| Fee waiver | −0.01% |
| Net expense ratio | 0.85% |
| Sales charges | |
|---|---|
| Max front load | — |
| Max deferred load | 0.00% |
| Redemption fee | — |
| Expense limitation in place (N-CEN) | Yes |
| Fees waived or reduced during the year | Yes |
| Waived fees subject to recoupment | No |
C000104936 Costs Over Time
On $10,000 invested in C000104936, assuming 5% a year before costs, total costs come to $550 over 5 years, cutting the return by 0.92% a year. Illustration, not a forecast: it assumes today's net expense ratio throughout (a fee waiver may end).
| $10,000 invested | Sell after 1 year | Sell after 3 years | Sell after 5 years |
|---|---|---|---|
| Value before costs | $10,500 | $11,576 | $12,763 |
| Fund expenses (net expense ratio 0.85%) | $89 | $279 | $484 |
| Trading costs (broker commissions) | $3 | $9 | $15 |
| Lost growth on money paid in costs | $0 | $14 | $50 |
| Total costs | $92 | $302 | $550 |
| Value after costs | $10,408 | $11,274 | $12,213 |
| Impact on return, per year | 0.92% | 0.92% | 0.92% |
C000104936 Trading Costs
Brokerage costs reported on SEC Form N-CEN for the fiscal year ending August 31, 2024.
- Explicit cost rate (commissions ÷ average net assets): 0.0271%
- Total broker commissions: $70K
- Bought from dealers (principal trades, not a cost): $146.9M
- Portfolio turnover (prospectus): 49%
- Securities lending: none during the year
C000104936 Agency Brokers
Commissions paid.
| Broker | Amount | Share |
|---|---|---|
| Royal Bank of Canada | $8K | 16.82% |
| Jefferies LLC | $7K | 14.23% |
| Merrill Lynch, Pierce, Fenner & Smith Incorporated | $5K | 10.27% |
| Cowen Execution Services LLC | $5K | 9.86% |
| UBS AG | $5K | 9.85% |
| J.P. Morgan Securities LLC | $4K | 9.28% |
| Citigroup Global Markets Holdings Inc. | $4K | 8.11% |
| Virtu Americas LLC | $4K | 7.79% |
| Goldman Sachs & Co. LLC | $3K | 6.91% |
| Bank of Montreal | $3K | 6.86% |
C000104936 Dealer Counterparties
Securities bought directly from dealers (principal trades).
| Broker | Amount | Share |
|---|---|---|
| T. Rowe Price Investment Services, Inc. | $72.4M | 49.27% |
| State Street Global Markets, LLC | $67.7M | 46.11% |
| Goldman Sachs & Co. LLC | $2.1M | 1.43% |
| J.P. Morgan Securities LLC | $1.5M | 1.05% |
| Pershing LLC | $1.4M | 0.96% |
| Jefferies LLC | $755K | 0.51% |
| Morgan Stanley & Co. LLC | $462K | 0.31% |
| Piper Jaffray & Co. | $399K | 0.27% |
| National Financial Services LLC | $71K | 0.05% |
| Cantor Fitzgerald & Co. | $54K | 0.04% |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.